BMS slams restricted NICE yes for Daklinza
This article was originally published in Scrip
Executive Summary
New draft guidance from NICE, the health technology appraisal institute for England, recommends Bristol-Myers Squibb's HCV pill Daklinza (daclatasvir), but only for just over half of patients eligible for treatment. The company has slammed the institute's decision, claiming that it leaves genotype 3 patients with few treatment options.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.